Saturday, July 4, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
DEFENSEHegseth's NATO Broadside and European Force Review Put Defense Primes in a Complicated SpottodayENERGYTalen Energy: The Merchant Nuclear Stock That Only Washington Can Break4 weeks agoTECHCommerce Department's AI Model Export Controls Are the Next Nvidia Headwind — and AMD Isn't ImmunetodayHEALTHCAREThe Medicare Drug Negotiation Trade: Who Gets Hurt When Washington Sets the Price4 weeks agoHEALTHCARE & FDAMedicare Is Now Covering Wegovy — Novo Nordisk and Eli Lilly Just Got a Massive New PayertodayENERGYBWXT: The Naval Nuclear Contractor Riding a Civilian Policy Wave4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Toddlers — Vertex and CRISPR Therapeutics Just Got a Bigger MarkettodayENERGYThe NRC Discount Helps Oklo More Than NuScale — Because NuScale Already Paid Full Price4 weeks agoWHITE HOUSETrump's Quantum Executive Order Sets a Hard Deadline — and Quantum Computing Stocks Are the Immediate BeneficiarytodayCRYPTOThe Anti-CBDC Play: No Digital Dollar Means Private Rails Win4 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Payday for AeroVironment — and a Warning Shot for Its RivalstodayENERGYForget Which Reactor Wins — GE Vernova Owns the Queue4 weeks agoTRADE & TARIFFSNike's Tariff Refunds Are a One-Time Boost, Not a Structural Fix — Here's What the Q4 Beat Actually MeanstodayCRYPTOThe Toll Booth at the Top of the Bitcoin ETF Stack4 weeks agoCRYPTOBitcoin Is Down 33% at Mid-Year and ETF Outflows Hit $4.3B in June — Coinbase and the Miners Are Feeling IttodayCRYPTOThe IRS Closes the Crypto Wash-Sale Loophole — and Robinhood Collects the Toll4 weeks agoENERGYWashington Is Rewriting Nuclear Radiation Safety Rules — Constellation, Vistra, and the SMR Crowd All WintodayENERGYCentrus vs. Cameco: Washington's Russian Uranium Ban Splits the Nuclear Fuel Chain4 weeks agoENERGYThe US-Iran Initial Deal Puts Sanction Relief on the Table — and That's a Headwind for Oil Prices and E&P StockstodayENERGYThe HALEU Contract Nobody Prices In4 weeks agoDEFENSEHegseth's NATO Broadside and Europe Force Review Signal a Shift That Benefits U.S. Primes — at Europe's ExpenseyesterdayCRYPTOThe Debanking Era Is Over. HOOD and Block Are Next in Line at the Window.4 weeks agoHEALTHCARE & FDAFDA's BHT and ADA Reassessment Puts Food Additive Suppliers on Notice — and Hands Clean-Label Brands a Marketing EdgeyesterdayENERGYWhy Constellation (CEG) Is Really a Policy Stock, Not a Utility Stock4 weeks agoHEALTHCARE & FDAMedicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential CustomersyesterdayCRYPTOMining the Grid: How EPA and Energy Policy Set the Spread for Proof-of-Work Miners4 weeks agoCRYPTOBitcoin ETF Outflows Hit $4.3 Billion in June — Coinbase, MARA, and Strategy Are Carrying the Most RiskyesterdayCRYPTOThe Stablecoin Bill: Who Controls the On-Ramp When Congress Licenses It4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger MarketyesterdayENERGYWillow Isn't an Oil Play. It's an Interior Department Play.4 weeks agoWHITE HOUSETrump's Quantum Executive Orders Set a 2030 Deadline — and a Spending Clock for IonQ, Rigetti, and the Cybersecurity StackyesterdayCRYPTOBitcoin as Reserve Asset: The Federal Legitimacy Trade4 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment — and Pressure on Its RivalsyesterdayENERGYWho Gets Exposed When the SPR Refill Never Happens4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger Market2 days agoENERGYWashington Fixed the LNG Permit. It Can't Fix a County Courthouse in Guilford County.4 weeks agoDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending Boom2 days agoENERGYThe Jones Act's Hidden LNG Winner: Foreign Tankers, Not U.S. Shippers, Cash In3 weeks agoDEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets Paid2 days agoCRYPTOThe SEC Retreat: How a Friendlier Regulator Unlocks Coinbase's Business Model3 weeks agoWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet Tailwind2 days agoENERGYHalliburton vs. SLB: Who Actually Cashes In on Methane Compliance3 weeks agoMARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big Tech2 days agoENERGYOccidental's Carbon Capture Isn't a Climate Bet. It's a Tax Credit Trade.3 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is Moving2 days agoTECHThe Federal Data Center Mandate: How Washington's AI Spending Flows to Hardware3 weeks agoTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real Money2 days agoTECHThe Domestic Equipment Play: How Foreign Chip Tool Restrictions Hand Applied Materials a Structural Edge3 weeks agoDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company Forever2 days agoENERGYSLB's Quiet Second Act: How Sanctions Reroute the Oilfield Services Backlog3 weeks agoDEFENSEWhy L3Harris Is Really a Policy Stock, Not a Hardware Stock3 days agoTECHThe AI Diffusion Rule Is Picking Winners Inside the Chip Stack — and It Is Not Who You Think3 weeks agoMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More Political3 days agoENERGYThe FERC Docket Nobody Reads: How Pipeline Certificates Quietly Pick LNG's Winners3 weeks agoTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to Watch3 days agoTECHThe HBM Monopoly: How Federal Memory Standards Lock In Micron3 weeks agoTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic Producers3 days agoTECHThe Tariff Arbitrage: How Chip Import Duties Reshape the Foundry Map3 weeks agoDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In Spending3 days agoENERGYWhy Williams (WMB) Is Really a Policy Stock, Not a Pipeline Stock3 weeks agoDEFENSESentinel vs. Columbia: The Nuclear Triad's Budget Is a Zero-Sum Game3 days agoENERGYDOE Reopens the LNG Export Spigot: Cheniere Cashes In First, Kinder Morgan Collects the Toll3 weeks agoDEFENSEThe FMS Loophole: How State Department Sign-Offs Insulate Defense Primes From Shutdown Risk4 days agoTECHThe Chip Stack Below the Pentagon's AI Buildup3 weeks agoDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Trade4 days agoDEFENSEHII's Mission Technologies: The Unsexy Segment Where Navy Autonomy Dollars Actually Land First3 weeks agoDEFENSEHII Is a Congressional Appropriations Bet, Not a Navy Bet5 days agoTECHThe CHIPS Act Subsidy Ladder: Who Actually Receives the $39 Billion3 weeks agoDEFENSEWho Actually Cashes In on 'Golden Dome': The Subcontractor Layer Behind LMT and RTX5 days agoDEFENSEThe Refueling Line Nobody Prices Into BWXT3 weeks agoDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligation5 days agoDEFENSEThe Law That Guarantees Matson a Buyer, No Matter the Price3 weeks agoDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Stream5 days agoENERGYThe Grid Hardening Bill Trade: How Federal Transmission Investment Lifts the Equipment Makers3 weeks agoDEFENSEThe Loser Nobody Names: Export Controls Squeeze Boeing From Both Sides6 days agoTECHThe Export Control Squeeze: BIS Chip Rules Are Splitting the AI Hardware Market in Two3 weeks agoDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own It6 days agoDEFENSEWho Loses if the Navy's 355-Ship Goal Quietly Becomes a 'Right-Sized Fleet' Retreat3 weeks agoDEFENSESole-Source vs. Full-and-Open: The Slow Bleed in LMT's F-35 Sustainment Machinelast weekENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom3 weeks agoDEFENSELeidos Is the Quiet Beneficiary of Every "Modernize Federal IT" Executive Orderlast weekDEFENSEMatson and the Jones Act: The Shipping Monopoly Washington Refuses to Touch3 weeks agoDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Programlast weekDEFENSEThe Real Winner Behind the Navy's Shipbuilding "Get Well" Plan Is Second-Tier Suppliers, Not the Primes2 weeks agoDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primeslast weekDEFENSELeidos: The Non-Obvious Beneficiary of Navy Digital and Sustainment Modernization2 weeks agoDEFENSEChina's Rare-Earth Squeeze Will Hit Defense Primes Unevenlylast weekENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear2 weeks agoENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oillast weekENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch2 weeks agoDEFENSERTX's Two-Front Bet: Why Iran Tensions and NATO's 5% Pledge Hit the Same Ticker Differentlylast weekDEFENSEAUKUS Pillar I Is a Slow-Burn Catalyst for GD and HII, Not a Pop2 weeks agoENERGYLNG Export Licenses: How a FERC Approval Mints a Monopolylast weekENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade2 weeks agoDEFENSEKratos vs. AeroVironment: Which One Actually Wins the Cheap-Drone-Swarm Pivotlast weekDEFENSEWhy BWXT Is Really a Policy Stock, Not an Industrial One2 weeks agoDEFENSEMercury Systems: The Toll Booth Every Drone and Missile Program Has to Pass Throughlast weekDEFENSEHII vs. General Dynamics: Who Wins the Submarine Industrial Base Money2 weeks agoENERGYThe BLM Calendar That Moves COP and OXYlast weekENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactors2 weeks agoENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Giftlast weekENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centrus2 weeks agoDEFENSEGolden Dome Is a Sensor and Software Story Before It's a Missile Storylast weekDEFENSEPalantir's Real Moat Is the Data Rights Clause, Not the AI2 weeks agoDEFENSEAxon Is a Homeland-Security Policy Stock Wearing a Police-Gear Disguiselast weekENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alive2 weeks agoENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keyslast weekDEFENSEElbit's America Problem: What Buy American Rules Really Do to a Foreign Prime2 weeks agoDEFENSEWho Actually Builds the Targets: The Overlooked Business Inside Kratoslast weekDEFENSECounter-Drone Spending Is the Quiet Twin of Drone Spendinglast weekDEFENSEThe Space-Based ISR Land Grab Nobody's Pricing In: Rocket Lab's Vertical Integration Betlast weekENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hublast weekENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deductionlast weekDEFENSELeidos: The Losing Trade When "Efficiency" Becomes the Watchword in Washingtonlast weekENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economicslast week
That's your last free article this week. Create a free account for 2 a week — or go Pro for everything.Go Pro →
Healthcare & FDA

FDA Expands Casgevy to Toddlers — Vertex and CRISPR Therapeutics Just Got a Bigger Market

Lowering the approved age for the first CRISPR gene therapy from 12 to 2 years old meaningfully expands the addressable patient pool.

Image: Money Racket
By at Money Racket · Jul 4, 2026

The FDA granted supplemental approval for Casgevy (exagamglogene autotemcel) in patients aged 2 and older with sickle cell disease or transfusion-dependent beta-thalassemia. Previously approved only for patients 12 and up, this expansion is the first gene therapy cleared for young children with sickle cell disease.

Who cashes in: Casgevy is co-developed and co-commercialized by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP). Both companies share economics on the therapy, which carries a list price of approximately $2.2 million per patient. Expanding the eligible population to children as young as 2 meaningfully increases the addressable market — sickle cell disease affects roughly 100,000 Americans, and earlier intervention is clinically preferred, meaning physicians now have a reason to refer younger patients. VRTX is the larger, more liquid name; CRSP is the higher-beta play on the same catalyst. bluebird bio (BLUE) has a competing gene therapy (Lyfgenia) for sickle cell, but its commercial trajectory has been rocky, and this approval puts more competitive pressure on its already-challenged position.

Dropping the approved age from 12 to 2 doesn't just expand the label — it expands the commercial opportunity before a competitor can get there.

Who's exposed: bluebird bio (BLUE) is the clearest loser. Its own sickle cell therapy competes directly with Casgevy, and an expanded Casgevy label means Vertex and CRISPR can now go after younger patients before bluebird can. Hydroxyurea manufacturers and chronic transfusion therapy providers face long-term volume pressure as curative gene therapies become accessible to younger patients — though the $2+ million price tag limits near-term penetration.

What to watch next: Payer coverage decisions. Medicaid covers a large share of sickle cell patients, and whether state Medicaid programs will cover Casgevy for pediatric patients is the gating factor on actual revenue. Watch for CMS guidance on gene therapy reimbursement frameworks.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →